319 related articles for article (PubMed ID: 18202672)
1. Forging synergies in drug discovery.
Nat Chem Biol; 2008 Feb; 4(2):83. PubMed ID: 18202672
[No Abstract] [Full Text] [Related]
2. Drug discovery: the leading edge.
Chapman T
Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608
[No Abstract] [Full Text] [Related]
3. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
4. Strength and honor through the pharmaceutical industry's embrace of green chemistry?
Fortunak J; Confalone PN; Grosso JA
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):651-3. PubMed ID: 17987518
[No Abstract] [Full Text] [Related]
5. Drug discovery.
Kennedy D
Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
[No Abstract] [Full Text] [Related]
6. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
7. New screening tools for lead compound identification.
Sawyer TK
Nat Chem Biol; 2005 Aug; 1(3):125. PubMed ID: 16408012
[No Abstract] [Full Text] [Related]
8. Hit and Lead identification: efficient practices for drug discovery.
Goodnow RA; Gillespie P
Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
[No Abstract] [Full Text] [Related]
9. Molecular medicine. NIH dives into drug discovery.
Couzin J
Science; 2003 Oct; 302(5643):218-21. PubMed ID: 14551416
[No Abstract] [Full Text] [Related]
10. Fragonomics: fragment-based drug discovery.
Zartler ER; Shapiro MJ
Curr Opin Chem Biol; 2005 Aug; 9(4):366-70. PubMed ID: 15925537
[TBL] [Abstract][Full Text] [Related]
11. Screening for drug discovery: the leading question.
Smith A
Nature; 2002 Jul; 418(6896):453-9. PubMed ID: 12140563
[No Abstract] [Full Text] [Related]
12. High-throughput and parallel screening methods in asymmetric hydrogenation.
Jäkel C; Paciello R
Chem Rev; 2006 Jul; 106(7):2912-42. PubMed ID: 16836304
[No Abstract] [Full Text] [Related]
13. Early chemical development at Legacy Wyeth Research.
O'Brien MK; Kolb M; Connolly TJ; McWilliams JC; Sutherland K
Drug Discov Today; 2011 Jan; 16(1-2):81-8. PubMed ID: 21111844
[TBL] [Abstract][Full Text] [Related]
14. Break with tradition.
Jayaraman KS
Nature; 2006 Jul; 442(7101):342-3. PubMed ID: 16871181
[No Abstract] [Full Text] [Related]
15. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
Beaumont K; Smith DA
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
[TBL] [Abstract][Full Text] [Related]
16. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
Wolfson W
Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
[No Abstract] [Full Text] [Related]
17. Pharma goes to work. Introduction.
Mervis J
Science; 2005 Jul; 309(5735):721. PubMed ID: 16051780
[No Abstract] [Full Text] [Related]
18. Unfinished business: target-based drug discovery.
Brown D
Drug Discov Today; 2007 Dec; 12(23-24):1007-12. PubMed ID: 18061878
[TBL] [Abstract][Full Text] [Related]
19. Fragmentary solutions. Astex therapeutics puts the pieces together.
Wolfson W
Chem Biol; 2006 Aug; 13(8):799-801. PubMed ID: 16931326
[No Abstract] [Full Text] [Related]
20. Knowledge-based chemoinformatic approaches to drug discovery.
Ghose AK; Herbertz T; Salvino JM; Mallamo JP
Drug Discov Today; 2006 Dec; 11(23-24):1107-14. PubMed ID: 17129830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
